Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Pennsylvania for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Pennsylvania only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Pennsylvania (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Yoshihiro Yonekawa (NPI 1962727008)

Field	Value
Entity Type	Individual
Organization	Yoshihiro Yonekawa
Address	4060 Butler Pike Ste 200
City	Plymouth Meeting
State	PA
ZIP	19462
Taxonomy	Ophthalmology Physician
NPI Enumerated	April 1, 2010

Payer Source	Total Paid
Medicare	$6.4M
Medicaid	$0

Key Findings

This provider’s billing is effectively single‑payer Medicare: lifetime Medicare revenue is $6.4M and there is no Medicaid billing on file, indicating Medicaid does not contribute to this provider’s reported revenue mix. The NPI was enumerated on 2010-04-01 (~16 years ago), consistent with an established practice presence in the market.

Revenue is highly concentrated in a small set of injection drugs: the precomputed top 3 Medicare codes account for 74.5% of this provider’s total Medicare revenue, driven by J0178 ($2.2M, 34.2%), Q5128 ($1.4M, 21.4%), and J2778 ($1.2M, 18.9%). These three codes together dominate the payer revenue profile and signal that a few high‑volume drug administrations are the primary business drivers.

The procedural and diagnostic mix points to a retina‑focused ophthalmology practice: large volumes of intravitreal drug administrations (J0178 3.2K claims, Q5128 6.3K claims, J2778 6.3K claims) paired with high retinal imaging (92134 5.3K claims) and intravitreal injection procedure coding (67028 3.6K claims) indicate routine, clinic‑based injection and imaging workflows rather than a general ophthalmology or purely surgical practice. This combination is characteristic of practices managing neovascular retinal disease with repeated in‑office injections and frequent OCT imaging.

Competitive standing for specific products is strong at a national level: Q5128 ranks #6 of 373 providers nationally (99th percentile; extreme outlier), J2778 ranks #26 of 1208 (98th percentile; notably above typical national volume), and J0178 ranks #145 of 3204 (96th percentile; notably above typical national volume). These ranks indicate the provider is a major national volume outlier for ranibizumab biosimilar use and among the higher‑volume administrators of ranibizumab and aflibercept.

High throughput is also evident in routine ophthalmic evaluation and imaging: 92012 has 2.8K claims and $183.4K revenue and ranks #24 of 17177 providers (100th percentile; extreme outlier), while 92134 ranks #35 of 26868 providers (100th percentile; extreme outlier). This suggests the practice sees a sustained flow of follow‑up visits and retinal imaging that supports frequent injection visits.

There is a notable disparity between claim count and revenue for some drugs: J2777 shows 12.6K claims but only $365.4K revenue (5.7% of Medicare revenue) with an average paid/claim of $29 and a national rank of #835 of 2039 providers (59th percentile; typical, unremarkable volume). By contrast, J3490 (unclassified drugs) has only 105 claims but $203.4K revenue (3.2%) with a $1937 avg paid/claim, indicating occasional high‑dollar items are billed under unclassified drug codes while other products generate many low‑unit payments.

The provider offers surgical/complex retina services but at modest volume relative to injections and imaging: codes such as 67108 (23 claims, $21.9K), 67113 (18 claims, $19.3K), and 67042 (15 claims, $13.8K) appear in the mix with typical national standing, indicating some capacity for retinal surgery or advanced procedures but not as the primary revenue stream. This supports a clinic model centered on chronic injection therapy with occasional retinal surgery.

Payer and pricing dynamics show wide variation in average paid/claim across the dominant codes: avg paid/claim ranges from $678 for J0178 to $216 for Q5128 and $190 for J2778, and these differences combine with high claim volumes to shape the revenue profile. Given the concentration in a few high‑volume, high‑revenue drug codes (74.5% share) and the lack of Medicaid billing, changes in Medicare drug reimbursement or utilization patterns for these specific codes would have outsized impact on this provider’s revenue.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

21 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0178	Injection, aflibercept, 1 mg	3,210	$680	$2.2M
Q5128	Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg	6,330	$220	$1.4M
J2778	Injection, ranibizumab, 0.1 mg	6,340	$190	$1.2M
J2777	Injection, faricimab‑svoa, 0.1 mg	12,600	$30	$365.4K
67028	The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye.	3,620	$100	$351.1K
J3490	Unclassified drugs	110	$1,940	$203.4K
92012	For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any…	2,820	$70	$183.4K
J2781	Injection, pegcetacoplan, intravitreal, 1 mg	1,520	$120	$181.8K
92134	The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes.	5,260	$30	$157.9K
92014	An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group…	710	$90	$60.7K

Showing 1–10 of 21

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 21 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Pennsylvania Distribution

Yoshihiro Yonekawa — 6 of 21 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Pennsylvania

Full comparison — all codes billed, vs. state median

21 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0178	16	140	830	$690	$865.1K
Q5128	3	20	3,830	$220	$838.7K
J2778	9	70	1,030	$190	$417.1K
J2777	31	100	7,950	$30	$360.2K
J2781	4	20	690	$120	$109.1K
67028	9	180	600	$90	$87.5K
J7999	80	110	100	$120	$33.3K
67042	36	50	20	$1,100	$31.9K
J3490	31	110	60	$70	$27.9K
92014	141	1,570	130	$80	$21K

Showing 1–10 of 21

Related Providers

Other providers that share a Tax Identification Number (TIN) with Yoshihiro Yonekawa, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
The Nemours Foundation	DE	Multi-Specialty Clinic/Center	$0	$172M
The Nemours Foundation	FL	Children's Hospital	$0	$104.9M
The Nemours Foundation	DE	Children's Hospital	$0	$104M
The Nemours Foundation	FL	Multi-Specialty Clinic/Center	$0	$46.2M
Nemours Children's Health, Downtown Orlando, Specialty Care	FL	Multi-Specialty Clinic/Center	$0	$44.4M
Nemours Children's Health, Jacksonville, Specialty Care	FL	Multi-Specialty Clinic/Center	$0	$23.6M
Sedigheh Ebadi	FL	Pediatrics Physician	$0	$10.1M
Children's Health Alliance, LLC	FL	Pediatrics Physician	$0	$9.6M
Omesh Gupta	PA	Ophthalmology Physician	$7.1M	$80
Mitchell Fineman	PA	Ophthalmology Physician	$7M	$0

Nearby Providers

Other providers in the same ZIP code as Yoshihiro Yonekawa, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Gemma Services	PA	Psychiatric Residential Treatment Facility	$0	$23.8M
Access Services Inc	PA	Community/Behavioral Health Agency	$0	$8.3M
Michael Klufas	PA	Ophthalmology Physician	$7M	$0
Richard Kaiser	PA	Ophthalmology Physician	$6.6M	$0
Allen Chiang	PA	Ophthalmology Physician	$6.6M	$0
Carl Regillo	PA	Ophthalmology Physician	$6.5M	$0
Allen Ho	PA	Ophthalmology Physician	$6.4M	$0
James Vander	PA	Ophthalmology Physician	$6.3M	$0
Marc Spirn	PA	Ophthalmology Physician	$6.3M	$0
Arunan Sivalingam	PA	Ophthalmology Physician	$6M	$0

Yoshihiro Yonekawa — Billing Profile & Reimbursement Data

Sign up for Yoshihiro Yonekawa — Billing Profile & Reimbursement Data policy alerts

Yoshihiro Yonekawa — Billing Profile & Reimbursement Data

Sign up for Yoshihiro Yonekawa — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References